

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

Silver State Scripts Board Meeting Minutes

Date of Meeting: Thursday, December 15, 2022, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFS), Silver State Scripts Board.

Agenda Item	Record	Notes																											
<p>1. Closed Executive Session</p> <p>a. Call to Order and Roll Call</p>	<p>Chairperson Mark Decerbo called the meeting to order at 1:00 p.m. on December 15, 2022.</p> <p>Chairperson Decerbo took the roll.</p> <table border="0"> <thead> <tr> <th></th> <th style="text-align: center;">Present</th> <th style="text-align: center;">Absent</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm. D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm. D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>DHCFS Staff Present were as follows:</p> <ul style="list-style-type: none"> • Lither, Gabriel, Senior Deputy Attorney General (SDAG) • Capurro, Antonina, Deputy Administrator • Olsen, David, Social Services Chief III • Gudino, Antonio, Social Services Program Specialist III (SSPS) • Berntson, Kindra, SSPS II • Flowers, Ellen, Program Officer I (PO)
	Present	Absent																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm. D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

		<p>Magellan Rx Staff Present were as follows:</p> <ul style="list-style-type: none"> • Mishra, Raj, Pharm.D., Clinical Account Manager • Kim, James, Pharm.D., Dir. Clinical Account Services • Martinez, Chris, Sr. Business Analyst • Chow, Connie, Pharm.D., Clinical Account Manager
<p>b. Financial Review of Drug Classes with Proposed Changes</p>	<p>Chairman Decerbo directed Dr. Raj Mishra to proceed with the Financial Review of Drug classes with proposed changes up for review.</p> <p>Dr. Mishra reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting</p> <p>Dr. Mishra presented the Financial Review of the News Drugs, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • Anticonvulsants • ADHD • Antidepressants, other <p>Dr. Mishra presented the Financial Review of the Established Drug Classes Being Reviewed due to Release of New Genetics, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • COPD <p>Dr. Mishra presented the Financial Review of the Established Drug Classes with Proposed Changes, noting the products with proposed changes in PDL status.</p> <ul style="list-style-type: none"> • NSAIDs 	

- Anti-Hypoglycemia
- Anti-Gout
- Anti-Hypertensive Agents
- Narcolepsy

2. Open Public Meeting

a. Call to Order and Roll Call

Chairman Decerbo called the meeting to order at 2:00 p.m. on December 15, 2022.

A quorum was present.

Chairman Decerbo took the roll.

	Present	Absent
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>
• Mark Crumby, Pharm. D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>
• Aditi Singh, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>

DHCFP Staff Present were as follows:

- Lither, Gabriel, SDAG
- Capurro, Antonina, Deputy Administrator
- Olsen, David, Social Services Chief III
- Gudino, Antonio, SSPS III
- Berntson, Kindra, SSPS II, Pharmacy Unit
- Ellen Flowers, PO I

Magellan Rx Staff Present were as follows:

- Mishra, Raj, Pharm.D., Clinical Account Manager
- Kim, James, Pharm.D., Dir. Clinical Account Services
- Martinez, Chris, Sr. Business Analyst
- Chow, Connie, Pharm.D., Clinical Account Manager

The public attendee list is included as Attachment A.

Note: Participants may not have chosen to reveal their

		identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured
b. Approval for previous Meeting Minutes from September 22, 2022	By unanimous consent, the minutes were approved as revised.	
c. Public Comments	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Joe Germaine regional account director with Bio Gen.</p> <p>Public comment was provided by Robin Reedy from Nami Nevada.</p>	
d. Status Update by DHCFP	<p>Chief of Pharmacy Services, David Olsen, provided several announcements.</p> <ul style="list-style-type: none"> • The Division of Healthcare Financing Policy would like to welcome Dr. Rashonda Clemens as the new Medicaid Medical Director. • We would like to publicly thank and recognize Dr. Mike Hautekeet. He has been a part of this board for quite some time. He has resigned his position and has entered into retirement but is with great thanks. We would like to acknowledge his service and the role that he played well in representing community pharmacists. • Nevada Medicaid has joined the National Medicaid Pooling Initiative (NMPI) and Diabetic Supply Pool on October 1st of this year. For more information you can contact Kristen Haloski at kmhaloski@magellanhealth.com. • Nevada Medicaid has established licensed pharmacists as a new provider type. Services related to dispensing self-administered contraceptives and prescribing HIV prevention medications are now reimbursable when provided by a pharmacist enrolled as a Nevada Medicaid provider. For more information on how to enroll as a 	

	<p>Nevada Medicaid provider, please visit the Provider Enrollment page that is found at the website www.medicaid.nv.gov.</p> <ul style="list-style-type: none"> On April 24th of next year, fee for-service Nevada Medicaid will implement a project that requires prior authorizations for a list of 60 specialty physician administered drugs. This project is specific to fee-for-service only. 	
3. Clinical Presentations		
A. For Possible Action: Discussion and possible adoption of Anticonvulsants		
i. <u>Public comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Brian Wensel the Health Economics and Outcomes Research Liaison with Synovia.</p> <p>Public comment was provided by Deb Profant Director of Pair Value and Outcomes for Jazz Pharmaceuticals.</p> <p>Public comment was provided by John Flatt Pediatric Neurologist and Medical Science Liaison from Marinus Pharmaceuticals.</p> <p>Public comment was provided by Mercedes Martin Medical Science Liaison for UCB.</p>	
ii. Drug class review presentation by MagellanRx	<p>Dr. Mishra discussed Ztalmy, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>	

<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Elizabeth Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan, and Board Member Joseph Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="688 451 1480 787"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended adding Ztalmy on the PDL as non-preferred.</p> <p>Moving Depakote ER to non-preferred and keeping generic as preferred.</p> <p>Moving Fintepla to non-preferred.</p> <p>Moving lamotrigine dose pack to non-preferred while keeping brand name as preferred.</p> <p>Moving Topamax to non-preferred while keeping generic as preferred.</p> <p>Moving Trileptal to non-preferred while keeping generic as preferred.</p> <p>Adding valproic acid solution as a preferred option.</p> <p>Zonegran will be removed from the PDL per policy due to non-participation in the Medicaid federal rebate program.</p>																																					

<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Sapandeeep Khurana moved to approve the proposed changes as presented by Magellan with the exception of grandfathering Fintepla and having Ztalmy as preferred and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 521 1476 857"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
<p>B. For Possible Action: Discussion and possible adoption of ADHD</p>																																						
<p>i. <u>Public comment</u></p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Opeoluwa Fagbemi with Qelbree</p>																																					
<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra discussed Xelstrym, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Mishra recommended the Board consider the class clinically and</p>																																					

		therapeutically equivalent.																																					
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Vice-Chair Kate Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	<p>Dr. Mishra recommended adding Xelstrym on the PDL as non-preferred.</p> <p>Moving clonidine ER to preferred.</p> <p>Moving Focalin XR to non-preferred while keeping generic as preferred.</p> <p>Moving Jornay PM to non-preferred.</p> <p>Moving methamphetamine to non-preferred.</p> <p>Moving Qelbree to non-preferred.</p> <p>Moving Strattera as non-preferred while keeping generic as preferred.</p>																																					
v.	Discussion by Board and action by Board for	Board Member Khurana moved to approve the proposed changes as presented by Magellan with the exception of leaving Jornay PM and Qelbree as preferred and Board Member Adashek seconded the motion.																																					

<p>approval of drugs for inclusion on the PDL.</p>	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="688 337 1480 673"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
<p>C. For Possible Action: Discussion and possible adoption of Antidepressants.</p>																																						
<p>i. <u>Public Comment</u></p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra discussed Auvelity, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</p> <p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Vice-Chair Ward seconded the motion.</p>																																					

<p>equivalency of agents in class.</p>	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="text-align: center;">Yes</th> <th style="text-align: center;">No</th> <th style="text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended adding Auvelity as non-preferred.</p> <p>Moving Forfivo XL to preferred and moving generic bupropion XL to non-preferred.</p> <p>Moving desvenlafaxine succinate ER to preferred.</p> <p>Removing desvenlafaxine fumarate ER due to manufacture discontinuation.</p> <p>Moving venlafaxine besylate ER to non-preferred while keeping venlafaxine hydrochloride ER as preferred.</p>																																					
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Adashek moved to approve the proposed changes as presented by Magellan and Vice-Chair Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="text-align: center;">Yes</th> <th style="text-align: center;">No</th> <th style="text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																													
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none"> • Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 																	
D. For Possible Action: Discussion and possible adoption of PDE-4 Inhibitors.																		
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border: none;"> <thead> <tr> <th style="width: 60%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															

	<ul style="list-style-type: none"> ● Mark Crumby, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> ● Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> ● Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> ● Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> ● Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding roflumilast on the PDL as preferred and moving Daliresp as non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Vice-Chair Ward moved to approve the proposed changes as presented by Magellan and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>● Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>● Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Aditi Singh, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
E. For Possible Action: Discussion and possible adoption of NSAIDS.																																						
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.																																					

	No public comment was provided.																																					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Vice-Chair Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended moving diclofenac potassium to non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Vice-Chair Ward moved to approve the proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		Yes	No	Abst.																																	
	Yes	No	Abst.																																			

	<ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 																	
For Possible Action: Discussion and possible adoption of COPD.																		
vi. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment provided.</p>																	
vii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																	
viii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.															
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															

	<ul style="list-style-type: none"> ● Mark Crumby, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> ● Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> ● Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> ● Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> ● Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 																																					
ix. Presentation of recommendations for PDL inclusion by MagellanRx	<p>Dr. Mishra recommended moving levalbuterol, levalbuterol HFA and Proventil HFA to preferred.</p> <p>Moving Xopenex and Xopenex HFA to non-preferred.</p>																																					
x. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Magellan and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th style="text-align: center;">Yes</th> <th style="text-align: center;">No</th> <th style="text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>● Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>● Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>● Aditi Singh, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	● Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
● Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
● Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
● Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
F. For Possible Action: Discussion and possible adoption of Anti-Hypoglycemic																																						

i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.																																					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Vice-Chair Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="688 732 1472 1068"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended to moving Gvoke Pen to preferred and keeping Gvoke syringe as non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Vice-Chair Ward moved to approve the proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>																																					

	<ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Joseph Adashek, MD <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Mark Crumby, Pharm.D. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Abst. • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Sapandeep Khurana, MD <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Aditi Singh, MD <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Abst. 	
G. For Possible Action: Discussion and possible adoption of Anti-Gout.		
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. 	

	<ul style="list-style-type: none"> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	<p>Dr. Mishra recommended moving allopurinol 200 mg to non-preferred while keeping allopurinol 100 and 300 mg as preferred.</p> <p>Moving Colcrys to non-preferred while moving generic colchicine tabs to preferred.</p>																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to approve proposed changes as presented by Magellan and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
H. For Possible Action: Discussion and possible adoption of Calcium-Channel Blockers																																						

i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding amlodipine/olmesartan to the class as preferred and moving amlodipine/valsartan/HCT as non-preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in</p>																																					

	<p>attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
I. For Possible Action: Discussion and possible adoption of Anti-Hypertensive Agents.																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					
ii. New Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Vice-Chair Ward seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																													
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none"> • Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended to add olmesartan and olmesartan HCTZ to the class as preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes by Magellan and Board Member Isabella Niezborala seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th style="text-align: center;">Yes</th> <th style="text-align: center;">No</th> <th style="text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
J. For Possible Action: Discussion and possible adoption of ACE Inhibitors.																																						
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.																																					

	No public comment was provided.																																					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommending moving Epaned solution to non-preferred and moving generic enalapril solution to preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>																																					

	<ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Joseph Adashek, MD <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Mark Crumby, Pharm.D. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Abst. • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Sapandeep Khurana, MD <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Aditi Singh, MD <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. 	
K. For Possible Action: Discussion and possible adoption of Anticonvulsants.		
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <ul style="list-style-type: none"> • Mark Decerbo, Pharm.D., Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Kate Ward, Pharm.D., Vice Chair <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Joseph Adashek, MD <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Abst. • Mark Crumby, Pharm.D. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Abst. 	

	<ul style="list-style-type: none"> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended move generic diazepam rectal to preferred.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th style="text-align: center;">Yes</th> <th style="text-align: center;">No</th> <th style="text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
L. For Possible Action: Discussion and possible adoption of Hydantoins																																						
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																					

<p>ii. Drug class review presentation by MagellanRx</p>	<p>Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
<p>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</p>	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Khurana seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 558 1474 889"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
<p>iv. Presentation of recommendations for PDL inclusion by MagellanRx</p>	<p>Dr. Mishra recommended moving Phenytek to non-preferred.</p>																																					
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="688 1294 1474 1391"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																									
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

	<ul style="list-style-type: none"> • Joseph Adashek, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Crumby, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Elizabeth Gonzalez, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Sapandeep Khurana, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 																													
M. For Possible Action: Discussion and possible adoption of Topical Analgesics																														
i. <u>Public Comment</u>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment provided.</p>																													
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Niezborala seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

	<ul style="list-style-type: none"> • Isabella Niezborala, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Aditi Singh, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 																																					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	<p>Dr. Raj Mishra recommended moving diclofenac 1% gel to preferred.</p> <p>Voltaren Gel will be removed from PDL due to non-participation in the Medicare Medicaid bill rebate program.</p> <p>Emla will be removed for PDL due to manufacture discontinuation.</p>																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Gonzalez moved to approve the proposed changes as presented by Magellan and Board Member Adashek seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Mark Decerbo, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Kate Ward, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Joseph Adashek, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Crumby, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Elizabeth Gonzalez, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Sapandeep Khurana, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Isabella Niezborala, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Aditi Singh, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Mark Decerbo, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Kate Ward, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Joseph Adashek, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Mark Crumby, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Elizabeth Gonzalez, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Sapandeep Khurana, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Isabella Niezborala, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Aditi Singh, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
N. MagellanRx Reports	<p>MRx Pipeline- Upcoming specialty and traditional Drugs</p> <ul style="list-style-type: none"> • Drugs in Pipeline- Alzheimer’s and Woman’s Health • December Trending Topics • RSV Updates • Recent FDA Approvals 																																					
O. Closing Discussion																																						

i. Public comments on any subject	No public comments were provided.	
ii. Date and location of the next meeting.	Date: March 23, 2023. Location: TBD	
iii. Adjournment	Chairman Decerbo adjourned the meeting at 3:28 PM.	

Attachment A – Members of the Public in Attendance

Abraham, Ron	GARCIA Fabiola	Martin Mercy	Sarah Cowan
Amy B	Hertzberg, Susan	Matthew Wright	Saunders-Newey, Tiffany N.
Arshad, Hilal	Jason C Bott	Name	Scurry Alexandra
Ashley Cruz	JATD (Jonathan Delgado)	Opeoluwa Fagbemi	Shelly Nickerson
Craig	John Flatt	Rianna White	Todd Dickerson
Craig Irwin	Johnson Sarah	Richard Maloy	Tory Johnson
Deb Profant	Karen Ou	Roa, Ryan A	Warner Quon
Donna Laffey	Lea Case	Robin Reedy NAMI Nv	Wensel, Brian
Eletreby, Iman	Levin, Amy, MD	Roshanda Clemons	Williams, Jameca
Fushimi Brent	Marc Rueckert	Saleeby, Jessica [JANUS]	

Attachment B – Submitted Written Comment

None